Universal CAR-T cells take on lupus and more in early trial

NCT ID NCT07246096

Recruiting now Disease control Sponsor: Changhai Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new type of CAR-T cell therapy (called KN3601) for people with severe autoimmune diseases like lupus, scleroderma, Sjögren's syndrome, rheumatoid arthritis, and vasculitis that haven't responded to standard treatments. The therapy uses specially engineered immune cells to target and potentially reset the immune system. The main goals are to check safety and see if it can control disease activity. About 60 adults aged 18 to 70 will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis autoimmune disease rheumatoid arthritis Sjogren syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS AUTOIMMUNE DISEASES PRIMARY SJÖGREN SYNDROME RHEUMATOID ARTHRITIS SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC SCLEROSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Changhai Hospital
RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••